Sage Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2012
Revenue	86.46	7.69	6.31	1,114	6.87	Upgrade
Revenue Growth (YoY)	1024.84%	21.85%	-99.43%	16123.06%	-92.39%	Upgrade
Cost of Revenue	2.16	0.81	0.55	0.57	0.4	Upgrade
Gross Profit	84.3	6.87	5.76	1,114	6.47	Upgrade
Selling, General & Admin	274.52	227.7	183.5	196.95	345.78	Upgrade
Research & Development	356.24	326.16	283.17	292.71	368.82	Upgrade
Other Operating Expenses	33.39	0	0	27.74	0	Upgrade
Operating Expenses	664.15	553.86	466.66	517.41	714.59	Upgrade
Operating Income	-579.85	-546.99	-460.91	596.23	-708.12	Upgrade
Other Expense / Income	-38.36	-14.21	-3.02	-9.85	-27.89	Upgrade
Pretax Income	-541.49	-532.78	-457.89	606.07	-680.24	Upgrade
Net Income	-541.49	-532.78	-457.89	606.07	-680.24	Upgrade
Shares Outstanding (Basic)	60	59	59	52	51	Upgrade
Shares Outstanding (Diluted)	60	59	59	53	51	Upgrade
Shares Change	0.89%	1.08%	10.69%	4.27%	10.22%	Upgrade
EPS (Basic)	-9.05	-8.98	-7.80	11.66	-13.38	Upgrade
EPS (Diluted)	-9.05	-8.98	-7.80	11.43	-13.38	Upgrade
Free Cash Flow	-541.14	-460.97	-378.55	663.94	-534.46	Upgrade
Free Cash Flow Per Share	-9.04	-7.77	-6.45	12.77	-10.51	Upgrade
Gross Margin	97.50%	89.42%	91.23%	99.95%	94.18%	Upgrade
Operating Margin	-670.69%	-7116.69%	-7306.74%	53.51%	-10310.48%	Upgrade
Profit Margin	-626.32%	-6931.88%	-7258.91%	54.40%	-9904.46%	Upgrade
Free Cash Flow Margin	-625.92%	-5997.57%	-6001.17%	59.59%	-7781.84%	Upgrade
EBITDA	-540.1	-531.66	-453.71	608.7	-677.96	Upgrade
EBITDA Margin	-624.71%	-6917.28%	-7192.61%	54.63%	-9871.21%	Upgrade
Depreciation & Amortization	1.39	1.12	4.18	2.63	2.28	Upgrade
EBIT	-541.49	-532.78	-457.89	606.07	-680.24	Upgrade
EBIT Margin	-626.32%	-6931.88%	-7258.91%	54.40%	-9904.46%	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).